ArticleFrontiers in human neuroscience2026
Cognitive impairment based on computerized testing among patients with major depressive disorder after remission.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate risk factors associated with cognitive impairment among patients achieving remission from major depressive disorder (MDD). Methods: This study was a retrospective analysis of data that had been prospectively collected from 1,227 patients diagnosed with MDD according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). Remission was defined as achieving a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HAMD-17) following treatment without the use of any antidepressants. Cognitive impairment was measured at 6 months after discharge using the computerized Testing with THINC-integrated tool. Patients' demographic variables, clinical factors and self-reported rating scores were analyzed using multiple logistic regression model. Results: 25.3% of patients exhibited cognitive impairment. Recurrent MDD (OR = 3.377, 95% CI: 1.629-7.003), increased inflammatory cytokines≥2 (OR = 4.032, 95% CI: 2.751-5.909), decreased dorsolateral prefrontal cortex volume (OR = 2.184, 95% CI: 1.298-3.676), decreased hippocampus volume (OR = 2.232, 95% CI: 1.393-3.576), increased amygdala volume (OR = 2.782, 95% CI: 1.751-4.420), decreased percentage of BOLD change for activity in subcortical network (OR = 2.689, 95% CI: 1.145-6.313) and ventral attention network (OR = 3.834, 95% CI: 1.573-9.345), increased percentage of BOLD change for activity in default mode network (OR = 5.136, 95% CI: 2.198-12.005) and Insomnia Severity Index scores ≥22 points (OR = 2.679, 95% CI: 1.502-4.779) were independent risk factors for cognitive impairment in remission from MDD. Receiver-operating characteristic curve demonstrated good predictive performance with area under the curve of 0.902. Conclusion: Our results identified factors associated with cognitive impairment in patients with MDD after remission, enabling improved monitoring and management for reducing these risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.